Media coverage about BioCryst Pharmaceuticals (NASDAQ:BCRX) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.5416689136639 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options (stockoptionschannel.com)
- Use of charts to make investment decisions about BioCryst Pharmaceuticals, Inc. (BCRX) – Wall Street Morning (wallstreetmorning.com)
- BioCryst Pharmaceuticals, Inc. (BCRX) registers a price change of 0.19% while Rosetta Genomics Ltd. (ROSG) finishes … – Stocks Gallery (stocksgallery.com)
- What Does Bollinger Band say about BioCryst Pharmaceuticals, Inc … – The Oracle Examiner (oracleexaminer.com)
- Buy Consensus rating Healthcare Stock: BioCryst Pharmaceuticals, Inc. (BCRX) – Street Observer (press release) (streetobserver.com)
Several equities research analysts have recently issued reports on the company. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. ValuEngine cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. Finally, BidaskClub lowered BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.78.
BioCryst Pharmaceuticals (BCRX) remained flat at $5.19 on Thursday. The stock had a trading volume of 1,121,264 shares. The firm has a 50-day moving average of $5.20 and a 200-day moving average of $5.69. The firm’s market cap is $417.42 million. BioCryst Pharmaceuticals has a 1-year low of $3.75 and a 1-year high of $9.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same period last year, the company earned ($0.22) EPS. The business’s quarterly revenue was down 35.4% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals will post ($0.75) earnings per share for the current fiscal year.
In other news, Director Fred E. Cohen sold 54,250 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 5.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BioCryst Pharmaceuticals (BCRX) Receiving Somewhat Favorable Media Coverage, Report Finds” was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/10/12/biocryst-pharmaceuticals-bcrx-receiving-somewhat-favorable-media-coverage-report-finds.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.